1. Introduction {#sec1-nutrients-11-01565}
===============

The gut microbiota, defined as the complex, diverse, and vast microbial community resided in the human gut, is emerging as a key player in the pathophysiology of several chronic conditions \[[@B1-nutrients-11-01565]\]. Gut microbiota extract energy from nutrients and regulate several biological processes. A microbiota imbalance, such as low abundance of *Akkermansia muciniphila* and *Faecalibacterium prausnitzii,* favours inflammatory processes, potentially leading to inflammatory disorders of the gastrointestinal tract such as irritable bowel syndrome and inflammatory bowel disease, as well as to colorectal cancer \[[@B2-nutrients-11-01565],[@B3-nutrients-11-01565],[@B4-nutrients-11-01565],[@B5-nutrients-11-01565],[@B6-nutrients-11-01565]\]. Also, increases in *A. muciniphila* and *F. prausnitzii* abundance can regulate metabolic functions and appear to exert protective effects against the development of obesity \[[@B7-nutrients-11-01565]\], type 2 diabetes (T2D) \[[@B8-nutrients-11-01565]\], and atherosclerosis \[[@B9-nutrients-11-01565]\]. Therefore, these two bacteria have been considered as potential bioindicators of human cardiometabolic health and conditions where underlying inflammation plays a role. *A. muciniphila* is a mucin-degrading bacterium of the phylum Verrucomicrobia, while *F. prausnitzii* is an important butyrate-producer of the phylum of Firmicutes. *F. prausnitzii* is also the major bacterium of the *Clostridium leptum* group \[[@B10-nutrients-11-01565],[@B11-nutrients-11-01565]\]. It accounts for 5% of total bacteria in faeces and it is an important source of energy for the colonocytes \[[@B12-nutrients-11-01565],[@B13-nutrients-11-01565]\].

Modulating the abundance of *A. muciniphila* and *F. prausnitzii* in the intestinal flora may contribute to prevent and treat inflammatory and cardiometabolic diseases \[[@B14-nutrients-11-01565],[@B15-nutrients-11-01565],[@B16-nutrients-11-01565]\]. Studies have shown that dietary factors can influence the diversity and composition of the gut microbiome more than human genetic factors \[[@B17-nutrients-11-01565]\]. Data from animal studies suggest that polyphenols-rich diets and specific phytochemicals such as curcumin and epigallocatechin gallate may improve the abundance of *A. muciniphila* and *F. prausnitzii* in the gut microbiome \[[@B18-nutrients-11-01565],[@B19-nutrients-11-01565],[@B20-nutrients-11-01565],[@B21-nutrients-11-01565],[@B22-nutrients-11-01565]\]. A clinical trial with obese insulin-resistant patients showed that resveratrol, a natural phenol, increased the abundance of *A. muciniphila* in Caucasians but not in other ethnic groups \[[@B23-nutrients-11-01565]\]. A diet high in fermentable oligo-, di- and monosaccharides and polyphenols (FODMAP), which has been implicated in digestive diseases such as irritable bowel syndrome, inflammatory bowel disease, and Crohn's disease, resulted in changes in gut microbiota including changes in *A. muciniphila* and *F. prausnitzii* but the evidence is not consistent \[[@B24-nutrients-11-01565],[@B25-nutrients-11-01565]\]. Furthermore, intake of dietary fibres, such as the soluble fibre inulin, has been associated with increased abundance of *A. muciniphila* and *F. prausnitzii* in healthy and overweight/obese individuals, but another study showed no influence of inulin intake on *F. prausnitzii* \[[@B26-nutrients-11-01565],[@B27-nutrients-11-01565],[@B28-nutrients-11-01565]\]. Despite the emerging evidence of the impact of dietary factors on changing the microbiome composition, a comprehensive assessment of the dietary interventions in modulating *A. muciniphila* and *F. prausnitzii* is lacking. Identifying dietary microbiome modulators may help understanding how diet and phytochemicals can be employed in medical nutrition therapy to increase the abundance of *A. muciniphila* and *F. prausnitzii*.

Therefore, the aim of this systematic review is to identify, integrate and discuss all available evidence from clinical trials in humans on the association of diet with changes in *A. muciniphila* and *F. prausnitzii*.

2. Material and Methods {#sec2-nutrients-11-01565}
=======================

2.1. Literature Search {#sec2dot1-nutrients-11-01565}
----------------------

This review was conducted and reported in accordance with the PRISMA \[[@B29-nutrients-11-01565]\] and MOOSE \[[@B30-nutrients-11-01565]\] guidelines ([Tables S1 and S2](#app1-nutrients-11-01565){ref-type="app"}). PubMed and Embase were used to identify published studies from database inception until April 23, 2019 (date last searched) that examined the associations between any dietary factor and changes in *A. muciniphila* and *F. prausnitzii* in humans. To capture all relevant studies, we used a broad search strategy using terms related to *A. muciniphila* and *F. prausnitzii* ([Appendix A](#app2-nutrients-11-01565){ref-type="app"}). We did not apply any restrictions with regard to language and date. Furthermore, to identify additional relevant studies, we checked the reference lists of the studies included in the current review.

2.2. Study Selection Criteria {#sec2dot2-nutrients-11-01565}
-----------------------------

To be included in the review, studies had to full-fill all of the following criteria: (i) were clinical trials (randomized placebo-controlled trials, randomized trials comparing different exposures and single-arm trials); (ii) included subjects 18+ years, and (iii) reported associations between any dietary intervention and absolute and relative abundance of *A. muciniphila*, or *F. prausnitzii*, or both. As we were interested to understand the effect of dietary factors on gut microbiome, we decided to include all trials irrespective of their aim; therefore, all eligible trials that reported baseline and end of study information on outcomes of interest were included in this review. Studies conducted in animals, children/teenagers, conference abstracts, letters to the editor, interventions examining probiotics solely and non-interventional studies were excluded. Following the selection criteria, two reviewers independently screened titles and abstracts for eligibility. Next, two reviewers assessed the full-text of potentially eligible studies. In cases of disagreement, a decision was made by consensus or, if necessary, a third reviewer was consulted.

2.3. Data Extraction {#sec2dot3-nutrients-11-01565}
--------------------

Two reviewers extracted the data independently using a predesigned form including study design, study population, location, age range, dietary intervention and control (if applicable), duration of intervention and study results.

2.4. Assessing the Quality of Trials {#sec2dot4-nutrients-11-01565}
------------------------------------

Two reviewers evaluated the risk of bias within each study using "The Cochrane Collaboration's tool" \[[@B31-nutrients-11-01565]\]. Studies were judged to be at low or high risk of bias based on criteria to evaluate random sequence generation, allocation concealment, blinding of participants/personnel and outcome assessment, incomplete outcome data and selective reporting. Trials were considered to be in low risk of bias if allocation concealment, blinding of participants and outcome assessors were all coded "yes", if a compliance assessment was done and the number of dropouts and reasons for dropout were reported; otherwise, the trials were considered to be at high risk of bias. If the risk of bias could not be determined in any of the segments, (e.g., information not provided) the risk of bias was classified as unknown. Lastly, for each trial, an overall score of quality was provided. Good quality was assigned when all criteria were met (i.e. low risk of bias for each domain). Fair quality was assigned when one criterion was not met (i.e. high risk of bias for one domain) or two criteria were unclear, and the assessment that this was unlikely to have biased the outcome, and there is no known important limitation that could invalidate the results. Poor quality was assigned when (i) one criterion was not met or two criteria were unclear, and the assessment that this was likely to have biased the outcome, and there are important limitations that could invalidate the results, or (ii) when two or more criteria were listed as high or unclear risk of bias.

3. Results {#sec3-nutrients-11-01565}
==========

3.1. Study Identification and Selection {#sec3dot1-nutrients-11-01565}
---------------------------------------

In total, we identified 1433 relevant citations. After screening based on titles and abstracts, 59 citations were selected for detailed full text evaluation. Of those, 30 articles \[[@B23-nutrients-11-01565],[@B24-nutrients-11-01565],[@B25-nutrients-11-01565],[@B26-nutrients-11-01565],[@B27-nutrients-11-01565],[@B28-nutrients-11-01565],[@B32-nutrients-11-01565],[@B33-nutrients-11-01565],[@B34-nutrients-11-01565],[@B35-nutrients-11-01565],[@B36-nutrients-11-01565],[@B37-nutrients-11-01565],[@B38-nutrients-11-01565],[@B39-nutrients-11-01565],[@B40-nutrients-11-01565],[@B41-nutrients-11-01565],[@B42-nutrients-11-01565],[@B43-nutrients-11-01565],[@B44-nutrients-11-01565],[@B45-nutrients-11-01565],[@B46-nutrients-11-01565],[@B47-nutrients-11-01565],[@B48-nutrients-11-01565],[@B49-nutrients-11-01565],[@B50-nutrients-11-01565],[@B51-nutrients-11-01565],[@B52-nutrients-11-01565],[@B53-nutrients-11-01565],[@B54-nutrients-11-01565],[@B55-nutrients-11-01565]\], based on 29 unique trials, met the selection criteria and were included in the review ([Figure 1](#nutrients-11-01565-f001){ref-type="fig"}). Among these, 19 articles examined *F. prausnitzii* \[[@B26-nutrients-11-01565],[@B27-nutrients-11-01565],[@B32-nutrients-11-01565],[@B34-nutrients-11-01565],[@B36-nutrients-11-01565],[@B37-nutrients-11-01565],[@B38-nutrients-11-01565],[@B39-nutrients-11-01565],[@B41-nutrients-11-01565],[@B42-nutrients-11-01565],[@B44-nutrients-11-01565],[@B46-nutrients-11-01565],[@B47-nutrients-11-01565],[@B49-nutrients-11-01565],[@B50-nutrients-11-01565],[@B51-nutrients-11-01565],[@B52-nutrients-11-01565],[@B54-nutrients-11-01565],[@B55-nutrients-11-01565]\], five articles examined *A. muciniphila* \[[@B23-nutrients-11-01565],[@B28-nutrients-11-01565],[@B35-nutrients-11-01565],[@B43-nutrients-11-01565],[@B48-nutrients-11-01565]\], and six articles examined both \[[@B24-nutrients-11-01565],[@B25-nutrients-11-01565],[@B33-nutrients-11-01565],[@B40-nutrients-11-01565],[@B45-nutrients-11-01565],[@B53-nutrients-11-01565]\].

3.2. Characteristics of the Included Trials {#sec3dot2-nutrients-11-01565}
-------------------------------------------

Of the 29 unique included trials, 15 were conducted in Europe, 8 in North America, 4 in Australia and New Zealand, 1 in Iran, and 1 in China; 22 were conducted among both men and women, 4 among men and 3 among women. Overall, the trials reported results for 1444 participants. All trials were published after 2005 and 80 percent in the last 5 years. The baseline age of the participants was 18+. The duration of the interventions ranged from 2 weeks to 6 months. The design of the included trials comprised randomized double-blind placebo-controlled trials, single-arm trials, multi-arm parallel trials, cross-over trials, and single and multi-centre trials. Detailed characteristics of the included trials are presented in [Table 1](#nutrients-11-01565-t001){ref-type="table"} and [Table 2](#nutrients-11-01565-t002){ref-type="table"}. Two trials scored an overall good quality score, indicating a low risk of bias in all domains ([Table S3](#app1-nutrients-11-01565){ref-type="app"}), whereas for the other trials the overall score was fair (*n* = 10) or poor (*n* = 18). There was a low risk of bias for all trials in the domain sequence generation and allocation concealment. For five trials, the risk of bias in the domain blinding of participants and personnel was unclear. In the domain blinding of assessment, 16 trials had an unclear risk of bias, as this was not clearly stated in these trials. Nine trials did not report how they handled missing data, and were therefore classified as being unclear in the assessment of risk of bias in the domain of missing data. High risk of bias was found in the domain of selective reporting for 14 trials, as they did not report effect estimates. The domain "other bias" included the risk of false positive findings for 14 trials, as these trials did not account for multiple testing in their analysis.

3.3. Trials Examining A. muciniphila {#sec3dot3-nutrients-11-01565}
------------------------------------

Eleven trials examined the association between a dietary intervention and *A. muciniphila* \[[@B23-nutrients-11-01565],[@B24-nutrients-11-01565],[@B25-nutrients-11-01565],[@B28-nutrients-11-01565],[@B33-nutrients-11-01565],[@B35-nutrients-11-01565],[@B40-nutrients-11-01565],[@B43-nutrients-11-01565],[@B45-nutrients-11-01565],[@B48-nutrients-11-01565],[@B53-nutrients-11-01565]\]. The dietary interventions examined were a caloric restriction diet, a reduced energy diet, a diet low in fermentable oligo-, di-, mono-saccharides and polyols (FODMAP), supplemental fibres, a yeast fermentate (EpiCor), sodium butyrare and inulin, pomegranate extract, kiwifruit capsules, and resveratrol. Findings are summarized in [Table 1](#nutrients-11-01565-t001){ref-type="table"}.

Dao M et al. evaluated a caloric restriction diet compared to a weight stabilization diet among overweight and obese participants \[[@B35-nutrients-11-01565]\]. In the caloric restricted group, the abundance of *A. muciniphila* decreased in participants with a high baseline level of *A. muciniphila* and increased in participants with low *A. muciniphila* levels. In the weight stabilization diet group, the abundance of *A. muciniphila* decreased in participants with both low and high baseline levels of *A. muciniphila*. Similarly to Dao M et al. \[[@B13-nutrients-11-01565]\], Medina-Vera I et al. examined a reduced energy diet compared to placebo in patients with T2D \[[@B45-nutrients-11-01565]\]. They reported that consumption of the reduced-energy diet increased levels of *A. muciniphila* by approximately 125%. However, two other studies coming from the same cross-over trial examined a diet low in FODMAPs compared to a typical Australian diet containing FODMAPs, and showed that the typical Australian diet increased absolute and relative abundance of *A. muciniphila* \[[@B24-nutrients-11-01565],[@B25-nutrients-11-01565]\].

A cross-over trial conducted showed that polydextrose supplementation increased *A. muciniphila* compared to soluble corn fibre supplementation or placebo (i.e. no supplemental fibre control) among healthy individuals \[[@B40-nutrients-11-01565]\]. Another cross-over trial reported no changes in relative or absolute abundance of *A. muciniphila* after increasing the intake of resistant starch and wheat bran foods among healthy individuals and patients with ulcerative colitis in remission \[[@B53-nutrients-11-01565]\]. Supplementation with EpiCor, a yeast fermentate, increased *A. muciniphila* compared to placebo (maltodextrin) in healthy individuals with moderate symptoms of gastrointestinal discomfort \[[@B48-nutrients-11-01565]\]. Supplementation with sodium butyrate or inulin increased *A. muciniphila* compared to placebo (starch) in overweight and obese diabetic patients, but no significant differences were found with combined sodium butyrate and inulin supplementation \[[@B28-nutrients-11-01565]\].

Pomegranate extract increased *A. muciniphila* by 47-fold in healthy metabolite urolithin A producers compared to non-producers \[[@B43-nutrients-11-01565]\]. However, kiwifruit capsules did not have a significant effect on *A. muciniphila* abundance in healthy and functionally constipated individuals \[[@B33-nutrients-11-01565]\]. Resveratrol supplementation led to an increase in *A. muciniphila* in USA Caucasians, but not in other ethnic groups \[[@B23-nutrients-11-01565]\].

3.4. Trials Examining F. prausnitzii {#sec3dot4-nutrients-11-01565}
------------------------------------

Twenty-five studies examined the effect of dietary interventions on *F. prausnitzii* \[[@B24-nutrients-11-01565],[@B25-nutrients-11-01565],[@B26-nutrients-11-01565],[@B27-nutrients-11-01565],[@B32-nutrients-11-01565],[@B33-nutrients-11-01565],[@B34-nutrients-11-01565],[@B36-nutrients-11-01565],[@B37-nutrients-11-01565],[@B38-nutrients-11-01565],[@B39-nutrients-11-01565],[@B40-nutrients-11-01565],[@B41-nutrients-11-01565],[@B42-nutrients-11-01565],[@B44-nutrients-11-01565],[@B45-nutrients-11-01565],[@B46-nutrients-11-01565],[@B47-nutrients-11-01565],[@B49-nutrients-11-01565],[@B50-nutrients-11-01565],[@B51-nutrients-11-01565],[@B52-nutrients-11-01565],[@B53-nutrients-11-01565],[@B54-nutrients-11-01565],[@B55-nutrients-11-01565]\]. Of these 25 studies, 17 studies examined prebiotics and the other studies examined isoflavones, dietary fat, carbohydrates, a ketogenic diet, kiwifruit capsules, sun-dried raisins, iron therapy, and a Chinese herbal formula. The findings are summarized in [Table 2](#nutrients-11-01565-t002){ref-type="table"}.

Treatment with prebiotic inulin-type fructans led to an increase of *F. prausnitzii* compared to placebo (maltodextrin) in obese women \[[@B36-nutrients-11-01565]\]. Supplementation of fructo-oligosaccharides, which are prebiotic fructans, increased the level of *F. prausnitzii* compared to placebo (maltodextrin) in patients with diarrhoea or mixed irritated bowel syndrome \[[@B41-nutrients-11-01565]\]. Supplementation of prebiotic inulin-oligofructose also increased the level of *F. prausnitzii* in healthy individuals \[[@B26-nutrients-11-01565]\]. Moreno-Indias I. et al. studied the prebiotic effect of red wine in male metabolic syndrome patients and healthy individuals and reported an increase of *F. prausnitzii* for red wine intake compared to baseline \[[@B46-nutrients-11-01565]\]. Another study found that *F. prausnitzii* was greater when healthy men consumed polydextrose or soluble corn fiber supplementation, which could be potential prebiotics, than when they consumed no supplemental fiber \[[@B40-nutrients-11-01565]\]. Medina-Vera I. et al. examined the effect of a reduced energy diet with prebiotic properties compared to a placebo diet in patients with type 2 diabetes, and reported an increase of *F. prausnitzii* of 34% \[[@B45-nutrients-11-01565]\]. Fernando WMU et al. studied the prebiotic potential of chickpea oligosaccharides (raffinose) alone or as components of chickpea and found that *F. prausnitzii* was more abundant in the raffinose diet and the chickpea diet compared to the control diet \[[@B38-nutrients-11-01565]\]. Ingestion of butyrylated high amylose maize starch led to greater relative increases of *F. prausnitzii* compared to ingestion of low amylose maize starch \[[@B55-nutrients-11-01565]\].

However, there are also studies reporting a decrease in *F. prausnitzii* after a prebiotic intervention. Patients from the intensive care unit starting nasogastric enteral nutrition receiving additional oligofructose/inulin had significantly lower concentration of *F. prausnitzii* compared to patients receiving placebo \[[@B44-nutrients-11-01565]\]. A combination of epigallocatechin-3-gallate and resveratrol decreased *F. prausnitzii* compared to placebo in obese men but not in obese women \[[@B47-nutrients-11-01565]\]. A cross-over trial comparing a fibre-free enteral formula or a formula supplemented with dietary fibre consisting of pea fibre and fructo-oligosaccharides showed large reductions in the number of *F. prausnitzii* during both the fibre-free and fibre-supplemented diets among healthy participants \[[@B52-nutrients-11-01565]\].

Moreover, some studies reported no differences in *F. prausnitzii* after a prebiotic intervention. Halmos E. et al. examined a diet low in FODMAPs compared to a diet containing FODMAPs in two different studies in patients with irritated bowel syndrome and patients with clinically quiescent Crohn's disease \[[@B24-nutrients-11-01565],[@B25-nutrients-11-01565]\]. They did not report significant differences in *F. prausnitzii* between the diets in both studies. Another study conducted among men with Crohn's disease examining the effect of fructo-oligosaccharides compared to a non-prebiotic carbohydrate also did not found differences in *F. prausnitzii* \[[@B32-nutrients-11-01565]\]. Vulevic J. et al. investigated the effect of administering Bi2muno (B-GOS) compared to placebo (maltodextrin) in a cross-over trial among overweight subjects predisposed to the development of metabolic syndrome, and reported no significant effects on counts of the *F. prausnitzii* cluster during the study \[[@B54-nutrients-11-01565]\]. Increasing the intake of resistant starch and wheat bran foods containing fibres did not change the relative and absolute abundance of *F. prausnitzii* in healthy participants and patients with ulcerative colitis in remission \[[@B53-nutrients-11-01565]\]. Among healthy individuals, Ramnani P. et al. studied the prebiotic effect of Jerusalem artichoke compared to a placebo, but did not report significant differences in *F. prausnitzii* \[[@B27-nutrients-11-01565]\].

Clavel T. et al. studied the effect of a prebiotic (isoflavones and fructo-oligosaccharides) or probiotic (isoflavones and *B. animalis* DN-173 010) compared to placebo (isoflavones alone) in postmenopausal women \[[@B34-nutrients-11-01565]\]. They reported that percentages of *F. prausnitzii* decreased significantly in control subjects compared to probiotic and prebiotic groups. Guadamuro L. et al. examined the effect of isoflavone concentrate supplementation alone in menopausal women and found an increase in the intensity of *F. prausnitzii* after isoflavone supplementation \[[@B39-nutrients-11-01565]\].

Fava F. et al. showed that the type and quantity of dietary fat and carbohydrate can alter faecal microbiome in individuals at increased risk of metabolic syndrome, whereby *F. prausnitzii* increased after intervention of a diet with high monounsaturated fatty acids and a high glycaemic index, compared to diets with high saturated fatty acids, high monounsaturated fatty acids in combination with a low glycaemic index, or with high carbohydrates in combination with high or low glycaemic index \[[@B37-nutrients-11-01565]\]. A ketogenic diet including a minimum of 0.8-1 gram per kilogram of bodyweight of protein from animal sources did not have an effect on *F. prausnitzii* \[[@B49-nutrients-11-01565]\]. Consumption of kiwifruit capsules increased *F. prausnitzii* abundance in functionally constipated individuals, compared to placebo \[[@B33-nutrients-11-01565]\]. Addition of sun-dried raisins to the diet also increased the abundance of *F. prausnitzii* among healthy individuals \[[@B50-nutrients-11-01565]\]. Oral iron therapy resulted in lower abundance of *F. prausnitzii* compared to intravenous iron therapy among iron deficient inflammatory bowel disease patients \[[@B42-nutrients-11-01565]\]. Xu J et al. examined the effect of a Chinese herbal formula (Gegen Qinlian Decoction) in a low, medium and high dose in recently diagnosed type 2 diabetes patients. They reported that all three doses of Gegen Qinlian Decoction treatment significantly enriched *F. prausnitzii* compared with baseline \[[@B51-nutrients-11-01565]\].

4. Discussion {#sec4-nutrients-11-01565}
=============

In the current systematic review of clinical trials, diet-induced changes in *A. muciniphila* and *F. prausnitzii* were reviewed. An increase in abundance of *A. muciniphila* was observed after a caloric restriction diet, supplementation with pomegranate extract, resveratrol, polydextrose, EpiCor or sodium butyrate, whereas a diet low in FODMAPs decreased the abundance of *A. muciniphila*. Prebiotics use was the main dietary intervention investigated in relation to *F. prausnitzii*, showing contradictory results depending on the type of prebiotics. Isoflavone supplementation and intake of some types of fatty acids, such as monounsaturated fatty acids, was associated with increased abundance of *F. prausnitzii*, whereas inulin intake and a reduced energy diet increased the abundance of both *A. muciniphila* and *F. prausnitzii*.

Approximately 100 trillion microorganisms are present in the body but mostly residing in the gastrointestinal tract \[[@B56-nutrients-11-01565]\]. In response to environmental changes, the gut microbiome can affect gene expression in humans. While around 23,000 genes make up the human genome, the microbiome consists over 3 million genes producing thousands of metabolites, and therefore affecting many aspects of human health, including gastrointestinal and cardiometabolic phenotypes \[[@B56-nutrients-11-01565],[@B57-nutrients-11-01565]\]. Changes in microbiota are observed in patients with inflammatory gastrointestinal disease, prediabetes, and T2D, particularly a decreased abundance of *A. muciniphila* and *F. prausnitzii* \[[@B58-nutrients-11-01565]\]. In addition, low abundance of *A. muciniphila* and *F. prausnitzii* has been associated with increased inflammatory processes and atherosclerosis, and *F. prausnitzii* transplantation has been shown to be an effective therapeutic approach for diabetes and its complications \[[@B59-nutrients-11-01565]\]. *F. prausnitzii* is an important butyrate-producer with anti-inflammatory properties, while *A. muciniphila* degrades mucin in the gut lining resulting in syntrophic interactions and stimulation of intestinal metabolite pool \[[@B60-nutrients-11-01565]\]. For example, co-cultivations of *A. muciniphila* with butyrate-producing bacteria resulted in syntrophic growth and butyrate production \[[@B60-nutrients-11-01565]\]. Butyrate plays an important role in anti-inflammation and maintaining intestinal barrier integrity by modulating intestinal macrophages' function, downregulating lipopolysaccharide-induced pro-inflammatory mediators, such as nitric oxide, IL-6, and IL-12, inducing the differentiation of regulatory T cells and stabilizing hypoxia-inducible factor \[[@B61-nutrients-11-01565],[@B62-nutrients-11-01565],[@B63-nutrients-11-01565],[@B64-nutrients-11-01565]\]. Further, butyrate can have beneficial effects on glucose and energy homeostasis by activating intestinal gluconeogenesis, as well as inducing apoptosis of colon cancer cells \[[@B65-nutrients-11-01565]\]. Studies in animal models have shown that colonization by *A. muciniphila* resulted in transcriptional changes, leading to an increase in the expression of genes associated with immune responses and cellular lipid metabolism \[[@B11-nutrients-11-01565],[@B66-nutrients-11-01565]\]. Besides degrading mucins, *A. muciniphila* can also stimulate mucin production, suggesting an autocatalytic process \[[@B67-nutrients-11-01565],[@B68-nutrients-11-01565]\]. Mucins are large, highly glycosylated proteins that play a crucial role in luminal protection of the gastrointestinal tract, thereby reducing translocation of pro-inflammatory lipopolysaccharides, controlling fat storage, adipose tissue metabolism, and glucose homeostasis \[[@B68-nutrients-11-01565],[@B69-nutrients-11-01565]\]. Therefore, altering the abundance and dynamics of these two strains of bacteria can lead to alterations in metabolic processes, and prevention and management of metabolic diseases.

Diet is the main source of energy to humans, but can also modulate microbiota and impact host-microbe interactions \[[@B70-nutrients-11-01565]\]. Therefore, gut microbiota may be crucial in mediating the health effects of foods. The gut microbiota provides the exoenzymes to catalyze and ferment substrates that cannot be completely digested by the human digestive tract to produce metabolites such as short fatty acids including butyrate \[[@B71-nutrients-11-01565]\]. Such non-digestible substrates include complex carbohydrates derived from plants and dietary fibres from cereals, legumes, vegetables, fruits, and nuts. Modulation of the gut microbiome through adherence to a high-fibre plant-based diet has been suggested as a potential therapeutic approach for prevention and treatment of inflammatory gastrointestinal diseases and metabolic diseases such as T2D and restoration of microbiota function \[[@B72-nutrients-11-01565],[@B73-nutrients-11-01565]\]. In line with this hypothesis, we found in the current review that inulin-type fructans, fructo-oligosaccharides, polydextrose or soluble corn fiber supplementation, and raffinose can lead to increase abundance of *A. muciniphila* and/or *F. prausnitzii*. However, we found no consistent associations or decreases for other types of prebiotics and abundance of *F. prausnitzii* such as inulin-oligofructose and resistant starch or wheat bran foods. Yet, this inconsistency is somehow expected considering that studies used different types of prebiotics, for which bacteria have differing specificity and therefore affecting differently the number of fermentable substrates in the gut \[[@B14-nutrients-11-01565]\]. In addition, different types of fibres have differing effects in the luminal pH and transit rate. Type of fibre being consumed, gut transit time, and the functional capabilities of gut microbiota influences the fermentation of carbohydrate and subsequent regional delivery of metabolites \[[@B14-nutrients-11-01565]\]. Hence, the different results we see in this study on the association between prebiotics and *F. prausnitzii* may reflect this complexity. This is also in line with the findings from observational studies showing that some types of dietary fibres (such as those from cereals) but not all are associated with reduced risk of T2D \[[@B74-nutrients-11-01565]\].

Pomegranate extract, a rich and varied source of polyphenolic compounds, and resveratrol polyphenol have been widely investigated for their antioxidant, anti-inflammatory, anti-diabetic and anti-atherogenic properties in both genders \[[@B75-nutrients-11-01565],[@B76-nutrients-11-01565]\]. Phytoestrogens seem to have similar effects but mainly in women; use of phytoestrogens in women is associated with improvement of menopausal symptoms, better glycaemic control and reduced risk of T2D \[[@B77-nutrients-11-01565],[@B78-nutrients-11-01565]\]. However, the mechanisms of action of these compounds remain unclear. Microbiome plays an important role in metabolizing the non-absorbed fraction of these compounds, and therefore defining the ability of these compounds such as polyphenols to exert health effects \[[@B79-nutrients-11-01565]\]. On the other hand, pomegranate and polyphenol resveratrol can modulate the abundance of *A. muciniphila*, while isoflavone phytoestrogens alone, and not in combination with fibres, can modulate the abundance of *F. prausnitzii* \[[@B19-nutrients-11-01565],[@B23-nutrients-11-01565],[@B34-nutrients-11-01565],[@B39-nutrients-11-01565],[@B43-nutrients-11-01565]\]. While it is not completely clear how such compounds can affect intestinal microorganisms, limited evidence suggests that it could be either by the selective pressure they exert on specific microorganisms, or by modifying environmental conditions of the intestinal tract \[[@B34-nutrients-11-01565]\].

Modifying the diet can lead to rapid changes in microbiota within the first days. A study reported human gut microbiome changes after only 24 hours after shifting between plant and animal protein-based diets \[[@B80-nutrients-11-01565]\]. Similarly, the studies included in this review showed that dietary interventions are associated with changes in *A. muciniphila and F. prausnitzii* in the first weeks of intervention \[[@B26-nutrients-11-01565],[@B41-nutrients-11-01565],[@B44-nutrients-11-01565],[@B50-nutrients-11-01565]\]. This suggests that diet may be an important and fast modifier of *A. muciniphila and F. prausnitzii,* and the microbiome in general, and a promising future therapeutic approach to prevent and treat inflammatory and metabolic conditions associated with specific microbiome strains. Our study highlights several additional factors that might be important to consider for a more comprehensive understanding of diet-related diseases and to elucidate the links between nutrition and dynamics of *A. muciniphila* and *F. prausnitzii*. However, dietary effects on microbiome may depend on health status, the baseline abundance of bacteria strains already in the gut, ethnicity, medication, and sex \[[@B24-nutrients-11-01565],[@B25-nutrients-11-01565],[@B32-nutrients-11-01565],[@B33-nutrients-11-01565],[@B34-nutrients-11-01565],[@B35-nutrients-11-01565],[@B37-nutrients-11-01565],[@B41-nutrients-11-01565],[@B42-nutrients-11-01565],[@B45-nutrients-11-01565],[@B46-nutrients-11-01565],[@B51-nutrients-11-01565]\]. This could also explain the inconsistent results across studies in this systematic review, as we included studies among different sexes, ethnicities and health statuses. For instance, men and women have different genetic background, energy and nutritional requirements across the lifespan, as well as differences in gastrointestinal transit time, which can contribute to sex differences in microbiome \[[@B81-nutrients-11-01565],[@B82-nutrients-11-01565]\]. Therefore, considering the sex-differences in the gut microbiome can provide novel insights in tailoring interventions and treatment, and therefore improving precision medicine. Machine-learning algorithms can help to predict inflammatory metabolic responses to meals, microbiome and how that differs by sex and ethnicity, and thus help to improve the emerging concept of personalized nutrition. For example, Zeevi et al. \[[@B83-nutrients-11-01565]\] used a machine-learning algorithm to predict personalised glucose responses after meals based on clinical and gut microbiome data. Based on the algorithm, a dietary intervention was designed and successfully shown to normalize blood glucose levels in a double-blinded randomised crossover trial of 26 patients \[[@B83-nutrients-11-01565]\]. Future research based on a large population-based studies and clinical trials is needed to evaluate a greater variety of food components and establish whether such personalised nutritional approaches based on microbiome composition are feasible and can improve clinical outcomes.

Further, it may be important to understand the differences that whole foods and ultra-processed foods may have on gut microbiota and subsequently on health outcomes. It has been shown that fibre-rich ultra-processed foods change the microbiota towards a less diverse and less beneficial composition compared to fibre-rich whole foods \[[@B84-nutrients-11-01565]\]. Processed foods have been undergone high heat and pressure, which can lead to several chemical and physical changes, including inactivation of endogenous enzymes, increased content of soluble dietary fibre and mechanical damage to the cell walls \[[@B85-nutrients-11-01565]\]. This suggests that whole unprocessed foods will enter the colon in an intact state which could favour the growth of bacteria that degrade fibre and produce beneficial metabolites, and thus exerting protective effects on health outcomes \[[@B85-nutrients-11-01565]\]. This theory is also supported from epidemiological studies showing that whole foods such as whole fish and whole grains can have a more beneficial effect than processed fish and refined grains, and that processed meat is in general associated with a stronger adverse health effect than whole meat \[[@B86-nutrients-11-01565]\]. Therefore, investigating the health effects of nutrients present in ultra-processed and whole food in the context of the microbiome can shed light on the mechanisms of the adverse effects of the Western diet.

To our knowledge, this is the first systematic review on the subject that critically and systematically appraised the literature on the effect of dietary interventions on *A. muciniphila* and *F. prausnitzii.* Nevertheless, some limitations from the included studies in this review merit careful consideration. Firstly, not all studies reported baseline and/or end of trial estimates between groups, and therefore the interpretation and the strength of the reported associations remained unclear. This and other factors (such as different types of study populations, interventions, and study designs) also limited providing a meaningful quantitative pooling of the existing data. It is important that future studies report summary estimates for all bacteria strains under investigation, and not apply selective reporting. Further, the studies included in this review were of suboptimal quality and the conclusions should be interpreted with caution. Most studies have been published in recent years and were conducted in limited sample sizes (16 studies had ≤30 participants) within interventions lasting short time periods (15 studies lasted for ≤6 weeks). Moreover, we cannot exclude the possibility that the changes we observed in *A. muciniphila* and *F. prausnitzii* are due to changes that dietary factors can lead to in the health condition of the participants, rather than the effect of diet alone. Nevertheless, most of clinical trials included in this review were performed in healthy individuals, and therefore we would expect that it is less likely that dietary factors we examined alter the abundances of the bacteria strains through changes in health. We also cannot exclude the possibility that the dietary factors lead to changes in other bacterial strains, which might have an effect on *A. muciniphila* and *F. prausnitzii*. What appears to be a promising field for intervention to improve health is also highly complex and new studies are required to untangle these complex interactions of diet, microbiome, and diseases in larger populations.

5. Conclusions {#sec5-nutrients-11-01565}
==============

In summary, we found that specific dietary interventions could influence the abundance of *A. muciniphila* and *F. prausnitzii*, highlighting a novel potential mechanism describing how diet can affect inflammatory and metabolic health outcomes. Understanding the links between different types of dietary interventions and changes in abundance of *A. muciniphila* and *F. prausnitzii* can help shaping future nutritional recommendations and designing medical nutrition therapies that can help prevent and treat diseases related to these two strains of bacteria such as inflammatory gastrointestinal disease and T2D.

The following are available online at <https://www.mdpi.com/2072-6643/11/7/1565/s1>, Table S1: PRISMA 2009 checklist, Table S2: MOOSE checklist, Table S3: The Cochrane Collaboration's tool for assessing risk of bias.
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Search Strategy
===============

PUBMED 384
----------

(akkermansia\[All Fields\] AND muciniphila\[All Fields\]) OR ("faecalibacterium prausnitzii"\[MeSH Terms\] OR ("faecalibacterium"\[All Fields\] AND "prausnitzii"\[All Fields\]) OR "faecalibacterium prausnitzii"\[All Fields\]) AND "humans"\[MeSH Terms\].

EMBASE 1049
-----------

(('akkermansia muciniphila\*': ab, ti OR 'faecalibacterium prausnitzii\*': ab, ti) OR ('akkermansia muciniphila'/exp OR 'faecalibacterium prausnitzii'/exp)) AND 'human'/de.

![Flowchart of studies included in the current review.](nutrients-11-01565-g001){#nutrients-11-01565-f001}

nutrients-11-01565-t001_Table 1

###### 

Descriptive Summary of Randomized Clinical Trials Investigating the Associations Between Dietary Interventions and Akkermansia Muciniphila.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Lead Author, Publication Year                                                        Study Design                                                  Location/Age Range   Individual Health Status                                                                                     Total Participants   Sex       Period of Intervention                                                         Dietary Treatment Characteristics                                                                                                          Main Findings                                                          
  ------------------------------------------------------------------------------------ ------------------------------------------------------------- -------------------- ------------------------------------------------------------------------------------------------------------ -------------------- --------- ------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Blatchford P et al. 2017\* \[[@B1-nutrients-11-01565]\]                              Randomized double-blind placebo-controlled cross-over trial   New Zealand/23--56   Healthy participants with no clinical symptoms of constipation and functionally constipated participants     29                   W and M   4 weeks each intervention (2 weeks washout period between each intervention)   ACTAZIN™ (600 mg/d) green kiwifruit extract low dose                                                                                       Placebo (isomalt coloured green 2400 mg/d)                             *A. muciniphila* was significantly more abundant in the functionally constipated group, but no effect of the interventions on *A. muciniphila.*

  ACTAZIN™ (2400 mg/d) green kiwifruit extract high dose                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Livaux™ (2400 mg/d) gold kiwifruit extract                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Dao M et al. 2015 \[[@B13-nutrients-11-01565]\]                                      Single-arm cross-over trial                                   France/41.9 ± 12.3   Overweight and obese participants                                                                            49                   W and M   12 weeks                                                                       Caloric restriction diet (1200 kcal/d for W and 1500 kcal/d for M)                                                                         Weight stabilization diet (prescribed individually by a dietitian)     Caloric restriction diet: Subjects with *A. muciniphila* at or above the median had a decrease in abundance of *A. muciniphila* while in the group with *A. muciniphila* lower than median there was an increase. The difference was statistical significant.\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       \
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Weight stabilization diet: In both subjects with *A. muciniphila* at or above and lower, there was a decrease in abundance of *A. muciniphila* with no difference between the groups.

  Halmos EP et al. 2015\* \[[@B16-nutrients-11-01565]\]                                Single-arm blinded randomized cross-over trial                Australia/18+        Healthy participants and participants with irritable bowel syndrome                                          33                   W and M   6 weeks                                                                        Diet low in FODMAPs                                                                                                                        Diet containing\                                                       Typical Australian diet increased absolute and relative abundance for mucus-associated *A. muciniphila* (*p* \< 0.001).
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                FODMAP content of a typical Australian diet                            

  Halmos EP et al. 2016\* \[[@B17-nutrients-11-01565]\]                                Single-arm blinded randomized cross-over trial                Australia/18+        Patients with clinically quiescent Crohn's disease                                                           9                    W and M   6 weeks                                                                        Diet low in FODMAPs                                                                                                                        Diet containing\                                                       Relative abundance was higher for mucus-associated *A. muciniphila* during the Australian compared with low FODMAP diet (*p* = 0.016).
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                FODMAP content of a typical Australian diet                            

  Hooda S et al. 2012\* \[[@B6-nutrients-11-01565]\]                                   Randomized double-blind placebo-controlled cross-over trial   USA/27.5 ± 4.33      Healthy participants                                                                                         25                   M         9 weeks                                                                        Polydextrose (PDX) (7 g, 3 times per day)                                                                                                  Placebo (no supplemental fiber control (NFC) (0 g, 3 times per day))   *A. muciniphila* was greater after PDX intake than after the NFC or SCF treatment (*p* \< 0.05).

  Soluble corn fiber (SCF) (7 g, 3 times per day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  James SL et al. 2015\* \[[@B54-nutrients-11-01565]\]                                 Randomized single-blind cross-over trial                      Australia/18--72     Patients with UC in remission and healthy subjects                                                           29                   W and M   8 weeks                                                                        'Low resistant starch (RS)/wheat bran (WB)' foods containing 2--5 g RS and\                                                                NA                                                                     Patients with UC had a lower abundance of *A. muciniphila*. For both cohorts, increasing the intake of RS/WB gave no indication of changes in relative or absolute abundance.
                                                                                                                                                                                                                                                                                                                                                                                                     2--5 g WB fibre per day                                                                                                                                                                                           

  'High RS/WB' foods containing 15 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  RS and 12 g WB fibre per day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Li Z et al. 2015 \[[@B20-nutrients-11-01565]\]                                       Single-arm trial                                              USA/28.9 ± 8         Healthy volunteers                                                                                           20                   W and M   4 weeks                                                                        Pomegranate extract\                                                                                                                       NA                                                                     The data were not shown for the overall population. *A. muciniphila* was 33 (at baseline) and 47 fold (after 4 weeks) higher in stool samples of Urolithin A producers compared to non-producers.
                                                                                                                                                                                                                                                                                                                                                                                                     (1000 mg)                                                                                                                                                                                                         

  Medina-Vera I et al. 2019\* \[[@B9-nutrients-11-01565]\]                             Randomized, double-blind placebo-controlled trial             Mexico/30--60        Patients with Type 2 Diabetes                                                                                81                   W and M   3 months                                                                       A reduced-energy diet with a dietary portfolio (DP) (14 g of dehydrated nopal, 4 g of chia seeds, 30 g of soy protein and 4 g of inulin)   Placebo (28 g of calcium caseinate and 15 g of maltodextrin)           DP consumption increased levels of *A. muciniphila* by approximately 125%.

  Pinheiro I et al. 2017 \[[@B11-nutrients-11-01565]\]                                 Randomized, double-blind placebo-controlled trial             Belgium/20--69       Healthy with reduced bowel movements and other symptoms of GI discomfort stratified in severe and moderate   80                   W and M   6 weeks                                                                        EpiCor fermentate (500 mg/d)                                                                                                               Placebo (maltodextrin (500 mg/d))                                      Significant relative increase of *A. muciniphila* in the moderate GI discomfort symptoms group at visit week 3 (*p* = 0.0001) and visit week 6 (*p* = 0.036).

  Roshanravan N et al. 2017 \[[@B25-nutrients-11-01565]\]                              Randomized, double-blind placebo-controlled trial             Iran/30--55          Overweight and obese diabetes patients                                                                       60                   W and M   6 weeks                                                                        Group A: Butyrate group (600 mg/d sodium butyrate + inulin placebo)                                                                        Butyrate + inulin placebo (6\                                          The percentage changes of *A. muciniphila* abundance indicated a significant increase in group taking sodium butyrate and inulin (group A and B) in comparison with the placebo group (*p* \< 0.05). A non-significant rise in this bacterium concentration was seen after supplementation with both sodium butyrate and inulin (group C).
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                starch capsules (100 mg) and 10 g of starch powder)                    

  Group B: inulin group (10 g/d inulin powder + butyrate placebo)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Group C: butyrate + inulin group (600 mg/d sodium butyrate + 10 g/d inulin powder)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  Walker JM et al. 2019 \[[@B27-nutrients-11-01565]\]                                  Randomized, double-blind placebo-controlled trial             USA/30--70           Obese insulin resistant subjects with metabolic syndrome                                                     28^a^                M         5 weeks                                                                        Resveratrol (500 mg Mega-RES 99% capsules twice daily)                                                                                     Placebo (two 500 mg placebo capsules twice daily)                      Overall, there was no difference. However, when split by ethnicity, resveratrol administration to Caucasian subjects led to an increase in *A. muciniphila* compared to the non-Caucasians.
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Studies examining both A. Muciniphila and F. Prausnitzii. FODMAPs Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols; FOS fructo-oligosaccharides; GI gastrointestinal; M men; NA not applicable; UC ulcerative colitis; W women. ^a^ Stool samples collected in 16 subjects.
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###### 

Descriptive Summary of Randomized Clinical Trials Investigating the Associations Between Dietary Interventions and Faecalibacterium prausnitzii.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Lead Author, Publication Year                                                                                 Study Design                                                              Location/Age Range       Individual Health Status                                                                                      Total Participants   Sex       Period of Intervention                                                         Dietary Treatment Characteristics                                                                                                                         Main Findings                                                                                                                                                       
  ------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- ------------------------ ------------------------------------------------------------------------------------------------------------- -------------------- --------- ------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Benjamin JL et al. 2011 \[[@B12-nutrients-11-01565]\]                                                         Randomized double-blinded placebo-controlled trial                        UK/39.5 ± 14.4           Patients with Crohn's disease                                                                                 103                  M         4 weeks                                                                        Normal diet supplemented with 15 g/day FOS, comprising fructose polymers of differing chain lengths                                                       Placebo (maltodextrin 15 g/day)                                                                                                                                     No significant differences between patients in the FOS and placebo group at week 4 (*p* = 0.95).

  Benus RFJ et al. 2010 \[[@B52-nutrients-11-01565]\]                                                           Randomized double-blinded cross-over trial                                UK/21--34                Healthy                                                                                                       14                   W and M   4 weeks                                                                        A formula supplemented\                                                                                                                                   NA                                                                                                                                                                  There were large and statistically significant reductions in the numbers of the *F. prausnitzii* group during both the fibre-free and fibre-supplemented diets. No differences between the fibre-free and fibre-supplemented diet (*p* = 0.23).
                                                                                                                                                                                                                                                                                                                                                                                                                                               with dietary fibre (14 g/l) consisting of pea fibre and fructo-oligosaccharides                                                                                                                                                                                                                                               

  A fibre-free enteral formula                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Blatchford P et al. 2017\* \[[@B1-nutrients-11-01565]\]                                                       Randomized double-blind placebo-controlled cross-over trial               New Zealand/23--56       Healthy participants who had no clinical symptoms of constipation and functionally constipated participants   29/W and M           W and M   4 weeks each intervention (2 weeks washout period between each intervention)   ACTAZIN™ L (600 mg/d)                                                                                                                                     Placebo (isomalt coloured green 2400 mg/d)                                                                                                                          *F. prausnitzii* abundance significantly increased from 3.4 to 7.0% following Livaux™ supplementation in the functionally constipated group (*p* = 0.024).

  ACTAZIN™ H (2400 mg/d)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Livaux™ (2400 mg/d)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        

  Clavel T et al. 2005 \[[@B2-nutrients-11-01565]\]                                                             Randomized double-blind placebo-controlled trial                          France/60.4 ± 7.1        Postmenopausal women                                                                                          39                   W         30 days                                                                        Probiotic group: isoflavones (100 mg/d) + *B. animalis* DN-173 010                                                                                        Placebo (isoflavones 100 mg/d)                                                                                                                                      Bacterial percentages for *F. prausnitzii* subgroup decreased significantly in control subjects compared to the probiotic and prebiotic group (*p* = 0.034).

  Prebiotic group: isoflavones (100 mg/d) + FOS (7 g/d)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Dewulf EM et al. 2012 \[[@B3-nutrients-11-01565]\]                                                            Double-blind placebo-controlled trial                                     Belgium/\                Obese                                                                                                         30                   W         3 months                                                                       ITF prebiotics (Synergy 1, namely, inulin/oligofructose 50/50 mix)                                                                                        Placebo (maltodextrin)                                                                                                                                              Treatment with ITF prebiotics, but not the placebo, led to an increase in *F. prausnitzii.*
                                                                                                                                                                                          47.5 ± 8.5                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Fava F et al. 2013 \[[@B14-nutrients-11-01565]\]                                                              Five-arm parallel, placebo-controlled, single-blind study                 UK/56.0 ± 9.5            Individuals at increased risk of metabolic syndrome                                                           88                   W and M   24 weeks                                                                       High SFA diet                                                                                                                                             NA                                                                                                                                                                  Numbers of *F. prausnitzii* increased after intervention with high CHO and low GI (*p* = 0.022) and high SFA (*p* = 0.018) diet compared to baseline.

  High MUFA/high GI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  High MUFA/Low GI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  High CHO/High GI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  High CHO/Low GI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Fernando WMU et al. 2010 \[[@B4-nutrients-11-01565]\]                                                         Randomized cross-over trial                                               Canada/25.6 ± 8.7        Healthy                                                                                                       12                   W and M   9 weeks                                                                        Control diet + 5 g/d raffinose                                                                                                                            Control diet                                                                                                                                                        *F. prausnitzii* was more abundant in the raffinose diet and the chickpea diet compared to the control diet.

  Control diet + 200 g/d canned chickpea                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  Guadamuro L et al. 2015 \[[@B15-nutrients-11-01565]\]                                                         Single-arm trial                                                          Spain/48--61             Menopausal women with no chronic disease                                                                      16                   W         24 weeks                                                                       One tablet isoflavoneconcentrate (80 mg) per day                                                                                                          NA                                                                                                                                                                  There was an increase in the intensity of *F. prausnitzii*.

  Halmos EP et al. 2015\* \[[@B16-nutrients-11-01565]\]                                                         Single-arm blinded randomized cross-over trial                            Australia/18+            Irritable bowel syndrome and healthy individuals                                                              33                   W and M   6 weeks                                                                        Diet low in FODMAPs                                                                                                                                       Diet containing\                                                                                                                                                    Low FODMAP diet reduced total bacterial abundance, but did not impact relative abundance of *F. prausnitzii.*
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         FODMAP content of a typical Australian diet                                                                                                                         

  Halmos EP et al. 2016\* \[[@B17-nutrients-11-01565]\]                                                         Single-arm blinded randomized cross-over trial                            Australia/18+            Patients with clinically quiescent Crohn's disease                                                            9                    W and M   6 weeks                                                                        Diet low in FODMAPs                                                                                                                                       Diet containing\                                                                                                                                                    No significant difference in *F. prausnitzii* between the two diets.
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         FODMAP content of a typical Australian diet                                                                                                                         

  Hooda S et al. 2012\* \[[@B6-nutrients-11-01565]\]                                                            Randomized double-blind placebo-controlled cross-over trial               USA/27.5 ± 4.33          Healthy                                                                                                       25                   M         9 weeks                                                                        Polydextrose (PDX) (7 g, 3 times per day)                                                                                                                 Placebo: no supplemental fiber control (NFC) (0 g, 3 times per day)                                                                                                 *F. prausnitzii* was greater in participants when they consumed PDX or SCF than when they consumed NFC (*p* \< 0.05).

  Soluble corn fiber (SCF) (7 g, 3 times per day)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Hustoft TN et al. 2016 \[[@B7-nutrients-11-01565]\]                                                           Randomized double-blind placebo-controlled cross-over trial               Norway/18--52            Diarrhea-predominant or mixed irritated bowel syndrome                                                        20                   W and M   10 days each intervention (3 weeks washout period)                             Fructo-oligosaccharides (FOS) 16 g/d                                                                                                                      Placebo: Maltodextrin 16 g/d                                                                                                                                        Ten days of FOS supplementation increased the level of *F. prausnitzii*.

  James SL et al. 2015\* \[[@B54-nutrients-11-01565]\]                                                          Randomized single-blind cross-over trial                                  Australia/18--72         Patients with UC in remission and healthy subjects                                                            29                   W and M   8 weeks                                                                        'Low resistant starch (RS)/wheat bran (WB)' foods containing 2--5 g RS and\                                                                               NA                                                                                                                                                                  For both cohorts, increasing the intake of RS/WB gave no indication of changes in relative or absolute abundance in *F. prausnitzii*.
                                                                                                                                                                                                                                                                                                                                                                                                                                               2--5 g WB fibre per day                                                                                                                                                                                                                                                                                                       

  'High RS/WB' foods containing 15 g\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  RS and 12 g WB fibre per day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Lee T et al. 2017 \[[@B19-nutrients-11-01565]\]                                                               Randomized, double-blind placebo-controlled trial                         Canada/18+               Iron deficient Inflammatory bowel disease patients                                                            72                   W and M   12 weeks                                                                       Oral iron sulfate 300 mg, tablet, twice a day                                                                                                             Iron sucrose, 300 mg, intravenous, three or four/day                                                                                                                Lower abundance of *F. prausnitzii* after oral iron therapy compared to intravenous iron therapy (*p* = 0.009).

  Majid HA et al. 2014 \[[@B8-nutrients-11-01565]\]                                                             Multi-centre, randomized double-blind controlled trial                    UK/70.8 ± 9.7            Patients from the ICU starting exclusive nasogastric enteral nutrition                                        22                   W and M   Up to 14 days                                                                  Oligofructose/inulin 7 g/d                                                                                                                                Placebo: maltodextrin 7 g/d                                                                                                                                         There were significantly lower concentrations of *F. prausnitzii* in patients receiving additional oligofructose/inulin (*p* = 0.01).

  Medina-Vera I et al. 2019\* \[[@B9-nutrients-11-01565]\]                                                      Single-centre randomized, controlled, double-blind parallel-group trial   Mexico/30--60            Patients with Type 2 Diabetes                                                                                 81                   W and M   3 months                                                                       A reduced-energy diet with a dietary portfolio (DP) comprising 14  g of dehydrated nopal, 4 g of chia seeds, 30 g of soy protein and 4 g of inulin        Placebo, comprising of 28 g of calcium caseinate and 15 g of maltodextrin.                                                                                          Dietary intervention with functional foods significantly modified faecal microbiota compared with placebo. DP consumption for 12 weeks increased levels of *F. prausnitzii* by approximately 34%.

  Moreno-Indias I et al. 2016 \[[@B21-nutrients-11-01565]\]                                                     Randomized, cross-over controlled trial                                   Spain/45--50             Metabolic syndrome and healthy individuals                                                                    20                   M         10 weeks (75 days)                                                             Red wine, 272 mL/day                                                                                                                                      De-alcoholized (no ethanol) red wine, 272 mL/dat                                                                                                                    In metabolic syndrome patients, there was a significant increase of *F. prausnitzii*, after the red wine and de-alcoholized red wine intake periods compared to baseline. In the healthy group, a significant increase in the number of *F. prausnitzii* through the intervention period was observed.

  Most J et al. 2017 \[[@B10-nutrients-11-01565]\]                                                              Randomized double-blind placebo-controlled trial                          The Netherlands/20--50   Obese                                                                                                         42                   W and M   12 weeks                                                                       A combination of epigallocatechin-3-gallate (EGCG) and resveratrol (RES) supplements (EGCG + RES; 282 and 80 mg/day, respectively)                        Placebo (partly hydrolyzed microcrystalline cellulose-filled supplements)                                                                                           EGCG+RES supplementation significantly decreased Bacteroidetes and tended to reduce *F. prausnitzii* in men (*p* = 0.05 and *p* = 0.10, respectively) but not in women (*P* = 0.15 and *P* = 0.77, respectively).

  Ramirez-Farias C et al. 2008 \[[@B23-nutrients-11-01565]\]                                                    Randomized, cross-over trial                                              UK/38.1 ± 2.43           Healthy adults                                                                                                12                   W and M   3 weeks                                                                        Inulin--oligofructose, 5 g, twice daily                                                                                                                   Did not consume any supplement                                                                                                                                      *F. prausnitzii* exhibited a significant increase after intervention (*p* = 0.019).

  Ramnani P et al. 2010 \[[@B24-nutrients-11-01565]\]                                                           Three-arm parallel, placebo-controlled, double-blind study                UK/18--50                Healthy adults                                                                                                60                   W and M   3 weeks intervention (3 weeks washout period)                                  Jerusalem artichoke (JA) inulin- predominantly made of pear-carrot-sea buckthorn and JA juices or purées (PCS); two 100 mL shots per day                  Placebo: Water-based preparation with added sugar, thickened and flavoured with blood orange, carrot and raspberry extracts and flavours (but no juice or purees)   No significant differences during the intervention and washout period.

  JA inulin- predominantly made of plum-pear-beetroot and JA juices or purées (PPB); Two 100 mL shots per day                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Tagliabue A et al. 2017 \[[@B26-nutrients-11-01565]\]                                                         Single-arm trial                                                          USA/18--34               Glucose Transporter 1 Deficiency Disorder (GLUT1-DS) patients                                                 6                    W and M   12 weeks                                                                       Ketogenic diet including a minimum of 0.8--1 gram per kilogram of body weight of protein from animal sources (e.g., eggs, milk, meat, poultry and fish)   NA                                                                                                                                                                  There was no statistical significant difference.

  Vulevic J et al. 2013 \[[@B55-nutrients-11-01565]\]                                                           Randomized double-blind placebo-controlled cross-over trial               UK/45.2 ± 11.9           Overweight subjects predisposed to the development of metabolic syndrome                                      45                   W and M   12 weeks each intervention (4 week washout period)                             Bi^2^muno (B-GOS)                                                                                                                                         Placebo (maltodextrin)                                                                                                                                              The two dietary interventions had no significant effects on counts of total bacteria and *F. prausnitzii* cluster during the study.

  West NP et al. 2013 \[[@B56-nutrients-11-01565]\]                                                             Randomized double-blind controlled trial                                  Australia/37.4 ± 8.4     Healthy active cyclists                                                                                       41                   W and M   28 days                                                                        Ingestion of 40 g/day of butyrylated high amylose maize starch (HAMSB)                                                                                    Low amylose maize starch (LAMS)                                                                                                                                     There were relative greater increases in faecal *F. prausnitzii* (5.1-fold; *p* \< 0.01) in the HAMSB group.

  Wijayabahu AT et al. 2019 \[[@B28-nutrients-11-01565]\]                                                       Single-arm trial                                                          USA/18--59               Healthy individuals                                                                                           13                   W and M   2 weeks                                                                        Sun-dried raisins:\                                                                                                                                       NA                                                                                                                                                                  *F. prausnitzii* significantly\
                                                                                                                                                                                                                                                                                                                                                                                                                                               Three servings per day; one serving contained 28.3 g raisins and 2 grams of dietary fiber                                                                                                                                                                                                                                     increased after the first week of raisin intake and this increase continued during the second week of raisin consumption (*p* \< 0.05).

  Xu J et al. 2015 \[[@B29-nutrients-11-01565]\]                                                                Randomized, double-blind placebo-controlled clinical trial                China/8.5 ± 2.6          Recently diagnosed type-2 diabetes patients                                                                   187                  W and M   12 weeks                                                                       Low dose of Gegen Qinlian Decoction                                                                                                                       Placebo                                                                                                                                                             All three doses of GQD treatment significantly enriched *F. prausnitzii* compared with baseline.

  Medium dose of Gegen Qinlian Decoction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

  High dose of Gegen Qinlian Decoction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* Studies examining both A. Muciniphila and F. Prausnitzii. CHO Carbohydrate; GI Glycemic index; FODMAPs Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols; FOS fructo-oligosaccharides; ICU intensive care unit; ITF Inulin-type fructans; M men; MUFA monosaturated fat; SFA Saturated fatty acids; UC ulcerative colitis; W women.
